Vaccine
& Prevention
Vacina & Prevenção
Palavras-chave: Alterações no receptor de células B (BCR), Análise de rede, Aprendizado de máquina, Bacilo Calmette-Guérin, CRISPR, BCG, Binding, Bioinformática, Candidatos a vacinas, Coronavírus, CRISPR, Desenvolvimento de vacina, DNA ambiental, Epidemiologia genômica, Escudo glicano, Estratégia de vacinação, Fase de Leitura Aberta 1ab, Genotipagem, Imunidade, Imunoinformática, Mamíferos, MEV, Modelis 3D, Monitoramento, Morcegos, Mutações, ORF3a, Perfil de células imunes, Pesquisas não-invasivas, Plasticidade genômica, Poliprolina, PPRs, Prophylactic Antiviral CRISPR in huMAN cells (PAC-Man), Profilaxia, Proteína glicosilada, Proteína S, Pseudovírus, Quasi-espécies polimórficas, Receptores, Reconhecimento da célula hospedeira, Resposta imune molecular, S309, Sarbecovirus subgenus, Sílica, Transmissão, Transmissão críptica, Tuberculose, Vacina recombinante, Vacinação, Vacinologia reversa.
Vaccine Targets & Development | Alvos & Desenvolvimento de Vacina
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. (Apr 19, 2020). Rapid development of an inactivated vaccine for SARS-CoV-2. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.04.17.046375
Xiong H, Wu Y, Cao J, Yang R, Ma J, Qiao X, et al. (Apr 13, 2020). Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.04.08.026948
Grant OC, Montgomery D, Ito K, Woods RJ (Apr 9, 2020). 3D Models of glycosylated SARS-CoV-2 spike protein suggest challenges and opportunities for vaccine development. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.04.07.030445
Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. (Apr 9, 2020). Structural and functional analysis of a potent sarbecovirus neutralizing antibody. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.04.07.023903
Yarmarkovich M, Warrington JM, Farrel A, Maris JM (Apr 2, 2020). A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.31.018978
Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M (Mar 28, 2020). Site-specific analysis of the SARS-CoV-2 glycan shield. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.26.010322
Milken Institute (updated Mar 23, 2020). COVID-19 Treatment and Vaccine Tracker. https://milkeninstitute.org/covid-19-tracker
Qamar MTu, Rehman A, Ashfaq UA, Awan MQ, Fatima I, Shahid F, Chen LL (Mar 22, 2020). Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.02.28.970343
Ong E, Wong MU, Huffman A, He Y (Mar 21, 2020). COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.20.000141
Prachar M, Justesen S, Steen-Jensen DB, Thorgrimsen S, Jurgons E, Winther O, Bagger FO (Mar 21, 2020). COVID-19 Vaccine Candidates: Prediction and Validation of 174 SARS-CoV-2 Epitopes. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.20.000794
Ibrahima IM, Abdelmaleka DH, Elshahata ME, Elfikya AA (Mar 10, 2020). COVID-19 spike-host cell receptor GRP78 binding site prediction. Journal of Infection [CORR. PROOF]. https://doi.org/10.1016/j.jinf.2020.02.026
Robson B (Feb 26, 2020). Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus. Computers in Biology and Medicine [CORR. PROOF]. https://doi.org/10.1016/j.compbiomed.2020.103670
Immunity Studies | Estudos sobre Imunidade
Weitz JS, Beckett SJ, Coenen AR, et al. (May 7, 2020). Modeling shield immunity to reduce COVID-19 epidemic spread. Nat Med [ONLINE]. https://doi.org/10.1038/s41591-020-0895-3
Wajnberg A, Mansour M, Leven E, et al. (May 5, 2020). Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region. medRxiv [PREPRINT]. https://doi.org/10.1101/2020.04.30.20085613
Wrapp D, Vlieger DD, Corbett KS, ..., Schepens B, Saelens X, McLellan JS (May 5, 2020). Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell 181:1-12. https://doi.org/10.1016/j.cell.2020.04.031
Ling N, Fang Y, et al. (May 3, 2020). Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity [PRE-PROOF]. https://doi.org/10.1016/j.immuni.2020.04.023
Long Q, Liu B, et al. (Apr 29, 2020). Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med [ONLINE]. https://doi.org/10.1038/s41591-020-0897-1
WHO (Apr 24, 2020). "Immunity passports" in the context of COVID-19. WHO [GUIDANCE]. https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19
Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. (Apr 22, 2020). Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv [PREPRINT]. https://doi.org/10.1101/2020.04.17.20061440
Wang B, Wang L, Kong X, Geng J, Xiao D, Ma C, et al. (Apr 21, 2020). Long-term Coexistence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) with Antibody Response in Coronavirus Disease 2019 (COVID-19) Patients. medRxiv [PREPRINT]. https://doi.org/10.1101/2020.04.13.20040980
Flodgren GM (Apr, 2020). COVID-19-EPIDEMIC: Immunity after SARS-CoV-2 infection—a rapid review. NIPH [MEMO]. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/immunity-after-sars-cov-2-infection-report-2020.pdf
Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. (Apr 6, 2020). Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.30.20047365
Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. (Apr 1, 2020). Virological assessment of hospitalized patients with COVID-2019. Nature [ONLINE]. https://doi.org/10.1038/s41586-020-2196-x
Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, et al. (Mar 27, updated Mar 31, 2020). Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell Sequencing. medRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.23.20039362
Dong C, Ni L, Ye F, Chen M-L, Feng Y, Deng Y-Q, et al. (Mar 20, 2020). Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2. medRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.17.20036640
Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. (Mar 14, 2020). Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.13.990226
Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, et al. (2017). T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Research 137, 82-92. https://doi.org/10.1016/j.antiviral.2016.11.006
Mutation Studies | Estudos sobre Mutação
Korber B, Fischer W, Gnanakaran SG, Yoon H, Theiler J, Abfalterer W, et al. (May 5, 2020). Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.04.29.069054
Yao H, Lu X, Chen Q, Xu K, Chen Y, Cheng L, et al. (Apr 23, 2020). Patient-derived mutations impact pathogenicity of SARS-CoV-2. medRxiv [PREPRINT]. https://doi.org/10.1101/2020.04.14.20060160
Farkas C, Fuentes-Villalobos F, Garrido JL, Haigh JJ, Barría MI (Apr 12, 2020). Insights on early mutational events in SARS-CoV-2 virus reveal founder effects across geographical regions. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.04.09.034462
Forster P, Forster L, Renfrew C, Forster M (Apr 8, 2020). Phylogenetic network analysis of SARS-CoV-2 genomes. PNAS [ONLINE]. https://doi.org/10.1073/pnas.2004999117
Karamitros T, Papadopoulou G, Bousali M, Mexias A, Tsiodras S, Mentis A (Mar 28, 2020). SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.27.009480
Issa E, Merhi G, Panossian B, Salloum T, Tokajian ST (Mar 28, 2020). SARS-CoV-2 and ORF3a: Non-Synonymous Mutations and Polyproline Regions. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.27.012013
Yin C (Mar 24, 2020). Genotyping coronavirus SARS-CoV-2: methods and implications. arXiv:2003.10965 [PREPRINT]. https://arxiv.org/abs/2003.10965
Wen F, Yu H, Guo J, Li Y, Luo K, Huang S (Mar 4, 2020). Identification of the hyper-variable genomic hotspot for the novel coronavirus SARS-CoV-2. J Infect [ONLINE]. https://doi.org/10.1016/j.jinf.2020.02.027
Bedford T (Mar 2, 2020). Cryptic transmission of novel coronavirus revealed by genomic epidemiology. Bedford Lab [BLOG]. https://bedford.io/blog/ncov-cryptic-transmission/
Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. (Feb 24, 2020). Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov 6, 11 (2020). https://doi.org/10.1038/s41421-020-0147-1
BCG Vaccine against COVID-19? | Vacina BCG contra COVID-19?
Szigeti R, Kellermayer D, Kellermayer R (Apr 11, 2020). BCG protects against COVID-19? A word of caution. medRxiv [PREPRINT]. https://doi.org/10.1101/2020.04.09.20056903
UMC Utrecht, Radboud University (updated Apr 3, 2020). Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA). NIH—US National Library of Medicine [CLINICAL TRIAL]. https://clinicaltrials.gov/ct2/show/NCT04328441
Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH (Mar 28, 2020). Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.24.20042937
Environmental DNA Surveys | Inspeções de DNA Ambiental
Alfano N, Dayaram A, Axtner J, Tsangaras K, Kampmann ML, Mohamed A, et al. (Mar 29, 2020). Non-invasive surveys of mammalian viruses using environmental DNA. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.26.009993
Markotter W, Geldenhuys M, Vuren PJV, Kemp A, Mortlock M, Mudakikwa A, et al. (Jul 2, 2019). Paramyxo- and Coronaviruses in Rwandan Bats. Trop. Med. Infect. Dis. 4(3), 99. https://doi.org/10.3390/tropicalmed4030099
Rizzo F, Edenborough KM, Toffoli R, Culasso P, Zoppi S, Dondo A, et al. (Dec 22, 2017). Coronavirus and paramyxovirus in bats from Northwest Italy. BMC Vet Res. 13: 396. https://doi.org/10.1186/s12917-017-1307-x
Other Prophylactic Studies | Outros Estudos Profiláticos
Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, et al. (Mar 14, 2020). Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza. bioRxiv [PREPRINT]. https://doi.org/10.1101/2020.03.13.991307
Gates B (Feb 28, 2020). Responding to Covid-19 — A Once-in-a-Century Pandemic? N Engl J Med 2020 [ONLINE]. https://doi.org/10.1056/NEJMp2003762
Gates B (May 31, 2018). Innovation for Pandemics (Shattuck Lecture). N Engl J Med 2018; 378:2057-2060. https://doi.org/10.1056/NEJMp1806283
Gates B (Apr 9, 2015). The Next Epidemic — Lessons from Ebola. N Engl J Med 2015; 372:1381-1384. https://doi.org/10.1056/NEJMp1502918